The European Commission said Illumina will have to restore Grail’s independence and return it to the same level that existed before the acquisition.
Source link
Tags: acquisitionsAcquisitions/MergersAcquisitions/Mergers/ShareholdingsAnti-Competition IssuesBiotechnologyBuyC&E Industry News FilterCancerCancerTestContent TypescorporateCorporate ActionsCorporate/Industrial NewsDealDeveloperDevelopmentEUFactiva Filtersgeneral newsgenomicsgrailHealthhealthcareHealthcare/Life SciencesIlluminaILMNindustrial newslife sciencesMedical ConditionsmergersOwnership ChangespoliticalPolitical/General NewsResearchResearch/DevelopmentshareholdingsSYNDtellsUnwindWSJ-PRO-WSJ.com
